BridgeBio and Yale initiate AI study for heart disease detection

PALO ALTO, Calif. - BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biopharmaceutical company, has announced a collaboration with Yale School of Medicine's CarDS Lab to improve the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), a frequently underdiagnosed heart condition. The TRACE-AI Network Study will leverage artificial intelligence (AI) to screen electronic health records (EHRs) across the United States, aiming to identify ATTR-CM earlier in patients and to estimate its prevalence.

The study will utilize a federated screening approach, applying AI tools like AI-electrocardiography (AI-ECG), AI-point-of-care ultrasound (AI-POCUS), and AI-echocardiography (AI-Echo) across multiple sites. This technology is expected to enhance early disease detection, particularly among populations that traditionally lack access to advanced diagnostics.

Jennifer Hodge, Ph.D., Vice President of Evidence Generation at BridgeBio, emphasized the company's commitment to computational strategies in drug discovery and now in disease detection. She stated that this initiative would address the unmet need for early ATTR-CM diagnosis in diverse populations.

Dr. Rohan Khera, who leads the CarDS Lab at Yale, highlighted the importance of the study's approach, which utilizes data accessible at the point of care to enable widespread deployment and access for disadvantaged groups.

Dr. Ahmad Masri, Cardiomyopathy Section Head at Oregon Health & Science University and a member of the TRACE-AI Network's Steering Committee, underscored the critical nature of early detection for ATTR-CM patients and the potential for improved outcomes.

The CarDS Lab will also present research funded by BridgeBio at the European Society of Cardiology's Congress 2024, including oral presentations and moderated posters on the application of AI in cardiac amyloidosis screening.

This initiative represents a significant effort to address the challenges of ATTR-CM diagnosis and underscores the potential of AI in improving healthcare outcomes. The study is based on a press release statement from BridgeBio Pharma, Inc.

In other recent news, BridgeBio Pharma announced a significant joint venture, GondolaBio, backed by a $300M investment from a consortium of investors. The formation of GondolaBio is a strategic move to accelerate the development of new therapies, with BridgeBio contributing early-stage clinical and pre-clinical programs.

The company also launched a new online platform, MyAchonJourney, in collaboration with QED Therapeutics to support individuals and families affected by achondroplasia.

In the realm of analyst ratings, Citi maintained a Buy rating on BridgeBio, while adjusting its price target. Other firms including Wells Fargo, Goldman Sachs, and BMO Capital Markets have also maintained positive ratings for the company.

BridgeBio has appointed Thomas Trimarchi, Ph.D., as its new President and Chief Operating Officer, expected to enhance efficiency across the company's late-stage pipeline.

In clinical trials, BridgeBio's Phase 3 FORTIFY study of BBP-418 exceeded its interim analysis enrollment target, with promising results shown in the Infigratinib trials.

Lastly, BridgeBio's annual meeting of stockholders resulted in the election of five Class II directors and the approval of key proposals, including the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

InvestingPro Insights

As BridgeBio Pharma, Inc. (NASDAQ:BBIO) embarks on a groundbreaking collaboration with Yale School of Medicine to advance the diagnosis of ATTR-CM using AI, investors may be curious about the company's financial health and market performance. Here are some insights based on real-time data from InvestingPro that could be particularly relevant to those following BridgeBio's endeavors:

InvestingPro Data indicates a remarkable revenue growth of 3761.22% over the last twelve months as of Q2 2024, reflecting a significant increase in the company's sales. This aligns with the InvestingPro Tip that analysts anticipate sales growth in the current year, suggesting that the market is optimistic about BridgeBio's revenue trajectory.

Despite the positive outlook on sales, analysts do not expect BridgeBio to be profitable this year. This is reflected in the company's high revenue valuation multiple and a negative P/E ratio of -9.79. The absence of profitability over the last twelve months is something investors may want to consider, especially when evaluating the company's long-term potential and the costs associated with its research and development efforts.

Moreover, BridgeBio's liquid assets exceed short-term obligations, as highlighted by another InvestingPro Tip. This could be a reassuring sign for investors, indicating that the company has a cushion to manage its short-term liabilities and invest in strategic initiatives like the TRACE-AI Network Study.

For readers interested in a deeper analysis, InvestingPro offers additional tips on BridgeBio Pharma, which can be accessed at https://www.investing.com/pro/BBIO. These insights can provide investors with a more comprehensive understanding of the company's financial position and market potential as they consider the impact of BridgeBio's AI-driven diagnostic advancements on its growth prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.